Cambridge, UK, Workshop Will Discuss Accelerated Preclinical Drug Development and Readying Molecules for Phase I

Share Article

The Catalent Applied Drug Delivery Institute today announced the latest in its series of educational workshops, entitled “From Discovery to Clinic: Getting Ready for Phase 1,” to discuss key considerations for the rapid and efficient transitioning of molecules from discovery, through to Phase 1 clinical trial readiness. The event content will include API and formulation development, clinical study design and regulatory requirements, and is to be held in collaboration with One Nucleus, the international membership organization for life science and healthcare companies, at Chesterford Research Park, Little Chesterford, UK, on April 20th, 2016.

Somerset, N.J. (PRWEB)April 07, 2016

The Catalent Applied Drug Delivery Institute today announced the latest in its series of educational workshops, entitled “From Discovery to Clinic: Getting Ready for Phase 1,” to discuss key considerations for the rapid and efficient transitioning of molecules from discovery, through to Phase 1 clinical trial readiness. The event content will include API and formulation development, clinical study design and regulatory requirements, and is to be held in collaboration with One Nucleus, the international membership organization for life science and healthcare companies, at Chesterford Research Park, Little Chesterford, UK, on April 20th, 2016.

The workshop starts at 9.00 a.m., and the agenda includes a presentation by Dr. John Knight, head of Jkonsult Ltd., providers of expert advice on chemical and process research and development, and people development, who will discuss the key priorities in the developmental process; and Malcolm Boyce, Medical Director of Hammersmith Medicine Research, one of the largest early-phase clinical trials units in Europe, who will draw upon his experience of being involved in over 670 phase I clinical trials and present “First-in-man studies: what we can achieve”. Also speaking will be Julien Meissonnier, Vice President, Science and Technology and Catalent Institute Board Member, who will discuss “Early dose form selection: selecting and optimizing formulation technologies for clinical success”; and Judith Jones from Catalent’s European Regulatory Affairs Department, who will present “Best Practices for preparing the IMPD quality section”.

The workshop will be the third in an ongoing series being held in European biotech research clusters. Previous events in Oxford, UK, and Copenhagen, Denmark, have brought together guest speakers including prominent academics, consultants, and technology representatives, alongside Catalent Institute and drug delivery and formulation experts. The agendas of each event have been designed to give the opportunity for biotech and life science companies to interact with industry experts and discuss some of the challenges faced by research teams within preclinical phases, to ensure drug candidates progressed to the clinic have the greatest chance of success at later stages of development.

There will also be an opportunity for companies attending the events to discuss active developmental programs in private with Catalent’s science and technology leaders.

One Nucleus is an international membership organisation for life science and healthcare companies. The organisation is based in Cambridge with the majority of its members across the Cambridge/London corridor, at the heart of Europe’s largest life science and healthcare cluster.

Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com